Solid Dosage Forms of Bendamustine
AssigneeAstellas Deutschland GmbH
InventorsJeffrey Colledge, Thomas Alfred Profitlich, Ulrich Patzak, Taoufik Ouatas, Margaretha Olthoff
Life of this patent
Estimating the term…
Loading patent…
AssigneeAstellas Deutschland GmbH
InventorsJeffrey Colledge, Thomas Alfred Profitlich, Ulrich Patzak, Taoufik Ouatas, Margaretha Olthoff
Estimating the term…
In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable or oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5.
A pharmaceutical composition in a solid dosage form suitable for oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester or a salt thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, selected from the group consisting of mannitol, maltitol, erythritol, xylitol, lactose, sucrose, glucose, sorbitol, maltose, trehalose, lactitol, dextrose, sucrose 97%+maltodextrin 3%, β-cyclodextrin, D-raffinose pentahydrate and D-melezitose monohydrate and microcrystalline cellulose, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5.
(canceled)
(canceled)
Dependencies are inferred from the claim text.